Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children

Live-attenuated respiratory syncytial virus vaccine with deletion of RNA synthesis regulatory protein M2-2 and cold passage mutations is over-attenuated

(2019) Coleen K Cunningham et al.   Open Forum Infectious Diseases

Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study

(2019) Katherine L. O'Brien et al.   LANCET

Live respiratory syncytial virus attenuated by M2-2 deletion and stabilized temperature sensitivity mutation 1030s is a promising vaccine candidate in children

(2019) Elizabeth J McFarland et al.   JOURNAL OF INFECTIOUS DISEASES

Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children

(2018) Ursula J Buchholz et al.   JOURNAL OF INFECTIOUS DISEASES

Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children

(2018) Elizabeth J McFarland et al.   JOURNAL OF INFECTIOUS DISEASES

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study

(2017) Ting Shi et al.   LANCET

Vaccines against respiratory syncytial virus: The time has finally come

(2016) Barney S. Graham   VACCINE

Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus

(2016) April M. Killikelly et al.   Scientific Reports

A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children

(2015) Ruth A. Karron et al.   Science Translational Medicine

A single amino acid in the F2 subunit of respiratory syncytial virus fusion protein alters growth and fusogenicity

(2013) H. A. Lawlor et al.   JOURNAL OF GENERAL VIROLOGY

Safety and Immunogenicity of a Live Attenuated RSV Vaccine in Healthy RSV-Seronegative Children 5 to 24 Months of Age

(2013) Elissa Malkin et al.   PLoS One

Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children

(2013) Janet A. Englund et al.   VACCINE

Respiratory Syncytial Virus Fusion Glycoprotein Expressed in Insect Cells Form Protein Nanoparticles That Induce Protective Immunity in Cotton Rats

(2012) Gale Smith et al.   PLoS One

Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years

(2011) Peter L. Collins et al.   VIRUS RESEARCH